Skip to content

G&A at other companies

NeoGenomics logo
NeoGenomicsNEO
$65.74M-3.6%
Veracyte logo
VeracyteVCYT
$23.68M-30.0%
CareDx logo
CareDxCDNA
$30.48M+33.9%

Segments

By segment

See full
Laboratory Services$20.05M-2.8%
Therapeutic Development$357K+36.8%

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$552.11M-7.1%
Enterprise value$536.92M+0.7%
P/S1.7×-0.3×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s G&A?
Fulgent Genetics, Inc. (FLGT) reported G&A of $27.68M in Q1 2026.
How has Fulgent Genetics, Inc.'s G&A changed year-over-year?
Fulgent Genetics, Inc.'s G&A increased by 9.5% year-over-year, from $25.29M to $27.68M.
What is the long-term trend for Fulgent Genetics, Inc.'s G&A?
Over 4 years (2021 to 2025), Fulgent Genetics, Inc.'s G&A has grown at a 23.1% compound annual growth rate (CAGR), from $50.73M to $116.66M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.